PE20130390A1 - Composiciones vacunales a base de sticholisina encapsulada en liposomas - Google Patents

Composiciones vacunales a base de sticholisina encapsulada en liposomas

Info

Publication number
PE20130390A1
PE20130390A1 PE2013000004A PE2013000004A PE20130390A1 PE 20130390 A1 PE20130390 A1 PE 20130390A1 PE 2013000004 A PE2013000004 A PE 2013000004A PE 2013000004 A PE2013000004 A PE 2013000004A PE 20130390 A1 PE20130390 A1 PE 20130390A1
Authority
PE
Peru
Prior art keywords
liposomes
sticholysin
encapsulated
compositions based
anemone
Prior art date
Application number
PE2013000004A
Other languages
English (en)
Inventor
Ruiz Maria Eliana Lanio
Molina Luis Enrique Fernandez
Quintana Rady Judith Laborde
Leal Yoelys Cruz
Lorenzo Maria Del Carmen Luzardo
Pardillo Circe Mesa
Valcarcel Carlos Manuel Alvarez
Santos Isabel Fabiola Pazos
Martinez Mayra Tejuca
Garay Aisel Valle
Biosca Maria Eugenia Alonso
Santos Liem Canet
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44533576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130390(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of PE20130390A1 publication Critical patent/PE20130390A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION DE VACUNA QUE CONTIENE UN VEHICULO PARA VACUNA QUE INDUCE UNA RESPUESTA INMUNE CELULAR Y COMPRENDE LA ENCAPSULACION EN VESICULAS LIPIDICAS DE PROTEINAS OBTENIDAS DE LA ANEMONA STICHODACTYLA HELIANTHUS TAL COMO StIW111C, StIW111Cirrev O StII INACTIVADA POR TRATAMIENTO TERMICO JUNTO CON UN ANTIGENO QUE ES UNA PROTEINA O POLIPEPTIDO ASOCIADO AL CANCER, SIDA O TUBERCULOSIS; EN DONDE LOS LIPOSOMAS SON OBTENIDOS POR EL PROCEDIMIENTO DE DESHIDRATACION-REHIDRATACION CUYA COMPOSICION LIPIDICA ES DIPALMITOILFOSFATIDILCOLINA:COLESTEROL EN UNA RELACION MOLAR 1:1
PE2013000004A 2010-07-06 2011-07-05 Composiciones vacunales a base de sticholisina encapsulada en liposomas PE20130390A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20100144A CU20100144A7 (es) 2010-07-06 2010-07-06 Composiciones vacunales a base de sticholisina encapsulada en liposomas

Publications (1)

Publication Number Publication Date
PE20130390A1 true PE20130390A1 (es) 2013-04-11

Family

ID=44533576

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000004A PE20130390A1 (es) 2010-07-06 2011-07-05 Composiciones vacunales a base de sticholisina encapsulada en liposomas

Country Status (24)

Country Link
US (1) US8697093B2 (es)
EP (1) EP2591802B1 (es)
JP (1) JP5685646B2 (es)
KR (1) KR101455055B1 (es)
CN (1) CN102971011B (es)
AR (1) AR081661A1 (es)
AU (1) AU2011276812B2 (es)
BR (1) BR112012033284B1 (es)
CA (1) CA2802443C (es)
CL (1) CL2012003674A1 (es)
CO (1) CO6640312A2 (es)
CU (1) CU20100144A7 (es)
EA (1) EA025333B1 (es)
ES (1) ES2576851T3 (es)
HK (1) HK1177138A1 (es)
MX (1) MX2012015173A (es)
MY (1) MY167896A (es)
PE (1) PE20130390A1 (es)
SG (1) SG186931A1 (es)
TN (1) TN2012000592A1 (es)
TW (1) TWI457145B (es)
UA (1) UA111944C2 (es)
WO (1) WO2012003814A1 (es)
ZA (1) ZA201300059B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6238366B2 (ja) * 2012-08-28 2017-11-29 国立大学法人北海道大学 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
EP3651733A4 (en) * 2017-07-10 2021-04-07 ImmunoVaccine Technologies Inc. PHARMACEUTICAL COMPOSITIONS, METHOD OF MANUFACTURING USING LIPID VESICLE PARTICLES OF DEFINED SIZE, AND USES THEREOF
CN113041346A (zh) * 2019-12-26 2021-06-29 复旦大学 一种细菌毒素疫苗及其在预防细菌感染中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2135406T3 (es) 1991-05-08 1999-11-01 Schweiz Serum & Impfinst Virosomas de la influenza reconstituidos inmunoestimulantes e inmunopotencializadores y vacunas que los contienen.
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
EP1797895A1 (en) 2005-12-16 2007-06-20 Pevion Biotech Ltd. An adjuvant system comprising virosomes and liposomes
AU2006351536B2 (en) 2006-12-04 2011-11-24 National Agriculture And Food Research Organization Method for producing biomineral-containing substance and organic hydroponics method

Also Published As

Publication number Publication date
ZA201300059B (en) 2013-09-25
CA2802443A1 (en) 2012-01-12
ES2576851T3 (es) 2016-07-11
TW201217000A (en) 2012-05-01
EP2591802A1 (en) 2013-05-15
SG186931A1 (en) 2013-02-28
AR081661A1 (es) 2012-10-10
BR112012033284A2 (pt) 2017-05-02
EA025333B1 (ru) 2016-12-30
TN2012000592A1 (en) 2014-04-01
AU2011276812A1 (en) 2013-01-10
CU20100144A7 (es) 2012-06-21
JP5685646B2 (ja) 2015-03-18
AU2011276812B2 (en) 2013-12-19
WO2012003814A1 (es) 2012-01-12
KR20130027547A (ko) 2013-03-15
CO6640312A2 (es) 2013-03-22
BR112012033284B1 (pt) 2021-05-18
CN102971011A (zh) 2013-03-13
US20130149376A1 (en) 2013-06-13
EP2591802B1 (en) 2016-06-08
EA201291449A1 (ru) 2013-05-30
KR101455055B1 (ko) 2014-10-28
CA2802443C (en) 2015-03-17
CN102971011B (zh) 2014-12-03
MY167896A (en) 2018-09-26
UA111944C2 (uk) 2016-07-11
CL2012003674A1 (es) 2013-07-12
US8697093B2 (en) 2014-04-15
TWI457145B (zh) 2014-10-21
JP2013530190A (ja) 2013-07-25
MX2012015173A (es) 2013-02-11
HK1177138A1 (en) 2013-08-16

Similar Documents

Publication Publication Date Title
AU2018201441B2 (en) Xten conjugate compositions and methods of making same
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
PE20161242A1 (es) Formulaciones de lipidos para la administracion de arn mensajero
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
MY169837A (en) Immunogenic compositions of staphylococcus aureus antigens
AR083561A1 (es) Preparacion de una construccion antigenica
UY31942A (es) Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones.
PE20130390A1 (es) Composiciones vacunales a base de sticholisina encapsulada en liposomas
AR085633A1 (es) Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
CL2011003091A1 (es) Composicion que comprende conjugado covalente entre hemoglobina funcional y nativa y al menos una molecula de polietilenglicol; metodo para preparar composicion; uso de dicha composicion para producir medicina de transfusion.
GT200900229A (es) Coagonistas de receptor de glucagón/glp-1
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
PE20140587A1 (es) Composicion de relleno que comprende un aceite encapsulado
UY29036A1 (es) Derivados de oxopiperidina, su preparacion y su aplicacion en terapeutica
CR8999A (es) Composicion para beber para el cuidado de la piel
AR100768A1 (es) Método para disminuir la inmunogenicidad de proteínas y péptidos
ECSP13012536A (es) Composiciones de anticuerpo y métodos de uso
UA110024C2 (uk) Вакцинний вектор і спосіб посилення імунної відповіді
EP2762153A3 (en) Vaccine composition for mucosal administration
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
ECSP088675A (es) Métodos y composiciones para actuar sobre relt
AR051046A1 (es) Proteina globular activada y su uso en composiciones comestibles

Legal Events

Date Code Title Description
FD Application declared void or lapsed